Pancreatic Stone Protein Testing Market

Future Market Insights suggests that within the pancreatic stone protein testing landscape, the emergence of rapid point-of-care PSP assays with 5-minute turnaround times is creating a measurable clinical advantage over established sepsis biomarkers such as procalcitonin and CRP. FMI analysts identify the FDA 510(k) clearance of the first PSP-based diagnostic platform as the central pivot point for the industry, effectively opening the world's largest acute care market to a biomarker previously confined to European and Swiss clinical practice.